# EDGAR Filing Document

**Accession Number:** 0001567892
**File Stem:** 0001104659-26-018824
**Filing Date:** 2026-2
**Character Count:** 93445
**Document Hash:** 825a0f73199e04ae74b7a10cc80122d3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-018824.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001104659-26-018824

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260223

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260224

**DATE AS OF CHANGE**: 20260224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Keenova Therapeutics plc
- **CENTRAL INDEX KEY:** 0001567892
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981088325
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35803
- **FILM NUMBER:** 26667528

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15
- **BUSINESS PHONE:** 353 1 6960000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** COLLEGE BUSINESS & TECHNOLOGY PARK
- **STREET 2:** CRUISERATH, BLANCHARDSTOWN
- **CITY:** DUBLIN 15
- **PROVINCE COUNTRY:** L2
- **ZIP:** D15

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mallinckrodt plc
- **DATE OF NAME CHANGE:** 20130125

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)** 

 **of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 23, 2026**

------

**Keenova Therapeutics plc**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Ireland** | **001-35803** | **98-1088325** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission <br> File Number)** | **(IRS Employer <br> Identification No.)** |

---

**College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland**

(Address of principal executive offices)

 **+353 1 6960000**

(Registrant's telephone number, including area code)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On February 23, 2026, ST Shared Services LLC, a subsidiary of Keenova Therapeutics plc (the "**Company**"), entered into the Fourth Amended and Restated Employment Agreement (the "**Employment Agreement**") with Sigurdur (Siggi) Olafsson. The Employment Agreement supersedes Mr. Olafsson's prior employment agreement with ST Shared Services LLC ("**Prior Agreement**"), which was disclosed in a Current Report on [Form 8-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001567892/000110465925065972/tm2519927d1_8k.htm) filed on July 7, 2025 (the "**Prior Form 8-K**"). The Prior Agreement provided that during the first half of 2026 Mr. Olafsson and the Company would discuss in good faith entering into a longer-term employment agreement. Pursuant to the Employment Agreement, Mr. Olafsson will remain in his role as Chief Executive Officer of ST Shared Services LLC and the Company until January 1, 2028 (the "**Expiration Date**"), and will be appointed as Chair of the Company's Board of Directors (the "**Board**") not later than May 14, 2026, provided that if a successor Chief Executive Officer is appointed prior to the Expiration Date, Mr. Olafsson's role will transition to Executive Chair of the Board (**"Executive Chair"**). If ST Shared Services LLC and Mr. Olafsson do not mutually agree to extend the term of Mr. Olafsson's employment prior to the Expiration Date, Mr. Olafsson's service as Chief Executive Officer, Chair and/or Executive Chair, as applicable, of the Company shall automatically terminate on the Expiration Date, which termination shall constitute a termination by the Executive with Good Reason (as defined in the Employment Agreement).

The Employment Agreement provides for the following compensatory arrangements for Mr. Olafsson, in addition to the inducement awards provided for in the Prior Agreement and disclosed in the Prior Form 8-K:

&nbsp;&nbsp;&nbsp;&nbsp;· *Cash Compensation.* Mr. Olafsson will be entitled to an annual base salary of $1,200,000 (which would be reduced by 20% in the
event that a successor Chief Executive Officer is hired prior to January 1, 2028 and Mr. Olafsson transitions to Executive Chair). Additionally,
Mr. Olafsson's annual cash bonus target and maximum cash bonus will be 200% and 400% of his annual base salary, respectively. The
actual bonus earned by Mr. Olafsson in respect of any given year, if any, will be based on performance metrics to be determined by the
Board or its delegate, the Human Resources and Compensation Committee of the Company, in its sole discretion, after consultation with
Mr. Olafsson. For any year in which Mr. Olafsson transitions to Executive Chair, Mr. Olafsson will be entitled to receive an annual bonus
(i) determined for the portion of the year prior to the transition on a pro-rata basis using the base salary that was in effect for that
period and (ii) determined for the portion of the year following the transition on a pro-rata basis using the base salary that was in
effect for the period following the transition, provided that the calculation of the bonus for any period when Mr. Olafsson is serving
as Executive Chair will be prorated using a level of performance that is not less than target.

&nbsp;&nbsp;&nbsp;&nbsp;· *Annual Long-Term Incentive Awards.* Beginning in the 2026 fiscal year, Mr. Olafsson will receive
 annual long-term incentive compensation grants, which in 2026 will be for awards of, in the
 aggregate, 152,722 restricted share units ()"**RSUs**") and performance restricted
 units ()"**PSUs**") and beginning in 2027 will have a grant date fair market
 value of no less than $11,500,000 (the "**Annual LTI Awards** "). The terms
 and conditions applicable to the Annual LTI Awards will be substantially consistent with
 the terms and conditions applicable to RSUs and PSUs (other than performance metrics) previously
 issued to Mr. Olafsson.

&nbsp;&nbsp;&nbsp;&nbsp;· *Founders Grant.* As part of one-time equity grants expected to be made to the Executive Team of the
 Company (such awards, "**Founders Grants** "), Mr. Olafsson will receive a
 Founders Grant in the form of RSUs, which will be in an amount no less than 2.3 times the
 number of RSUs granted to the individual who receives the second largest Founders Grant.
 The RSUs will vest ratably on each of the first through third anniversaries of the grant
 date, subject to his continued service through such date. The terms and conditions of such
 Founders Grant will be substantially consistent with the terms and conditions applicable
 to RSUs previously issued to Mr. Olafsson.

Under the terms of the Employment Agreement, in the event that Mr. Olafsson's employment is terminated by ST Shared Services LLC without Cause, by Mr. Olafsson with Good Reason or as a result of his death or Disability (as each term is defined in the Employment Agreement), Mr. Olafsson will be entitled to the following severance compensation and benefits: (a) a lump sum cash payment equal to 2.5 times the sum of his annual base salary and target annual bonus; (b) a lump sum payment of the cash inducement award, which was described in the Prior Form 8-K (if not yet paid) and the prorated portion of the target annual bonus with respect to the year in which the termination occurs; (c) immediate vesting of the equity inducement award, which was described in the Prior Form 8-K, and Founders Grant; (d) any Annual LTI Awards granted in 2026 or later will be treated in accordance with the applicable plan and related award agreements, provided that, notwithstanding anything in the applicable plan or award agreements to the contrary, to the extent Mr. Olafsson's termination for Good Reason is as a result of the parties failing to agree to extend the term beyond the Expiration Date, Mr. Olafsson will immediately vest in any RSUs that would have otherwise vested in the first quarter of 2028 and will immediately vest in a prorated portion of the target number of PSUs subject to such awards, and the balance of such awards will be forfeited; (e) except as otherwise set forth in the Employment Agreement, all outstanding equity-based awards granted under the Mallinckrodt Pharmaceuticals 2024 Stock and Incentive Plan or the Keenova Therapeutics plc 2025 Stock and Incentive Plan will be treated in accordance with the terms of the applicable plan and related award agreements; and (f) continued COBRA coverage or, if no longer eligible for Company-provided COBRA, monthly cash payments equal to the applicable COBRA premium amount for up to 30 months following Mr. Olafsson's termination.

The Employment Agreement provides that Mr. Olafsson will be restricted from soliciting the Company's employees and business partners during the 12-month period following his termination of employment for any reason (the "**Restricted Period**"). The Employment Agreement also provides that Mr. Olafsson will be restricted from competing with the Company, its subsidiaries or affiliates during the Restricted Period, provided that the Restricted Period will not apply following Mr. Olafsson's termination of employment if the date of termination is on or after the Expiration Date or if Mr. Olafsson's employment is terminated by ST Shared Services LLC without Cause or by Mr. Olafsson with Good Reason.

The foregoing description of the Employment Agreement is qualified in its entirety by reference to the Employment Agreement, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description of Exhibit** |
| [10.1](tm267041d1_ex10-1.htm) | [Fourth Amended and Restated Employment Agreement, by and between ST Shared Services LLC and Sigurdur Olafsson, dated February 23, 2026.](tm267041d1_ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **KEENOVA THERAPEUTICS PLC** | **KEENOVA THERAPEUTICS PLC** |
| (registrant) | (registrant) |
| By: | /s/ Mark Tyndall |
|  | Mark Tyndall |
|  | Executive Vice President, Chief Legal Officer & Corporate Secretary |

---

Date: February 24, 2026

## Exhibit 10.1

**Exhibit 10.1**

**FOURTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT**

This **FOURTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT** (this "***Agreement***"), is entered into on February 23, 2026 (the ***"Effective Date"***), by and between ST Shared Services LLC, a Delaware limited liability company, or any successor thereto (the "***Company***"), and Sigurdur Olafsson (the "***Executive***").

WHEREAS, the Executive is currently a party to that certain Third Amended and Restated Employment Agreement, entered into on July 7, 2025, by and between the Company and the Executive (the ***"Prior Agreement"***), pursuant to which the Executive is employed as the Chief Executive Officer of the Company and, in connection therewith but for no remuneration, the Executive serves as a member of the board of directors and Chief Executive Officer of Keenova Therapeutics plc, a public company with limited liability incorporated in Ireland ("***Keenova***" and, collectively with the Company and their respective subsidiaries and affiliates (but excluding, for the avoidance of doubt, any creditors of Keenova, the Company and their respective subsidiaries and affiliates and any entities owned by such creditors that are not otherwise related to Keenova), the "***Company Group****"*);

WHEREAS, the term of the Prior Agreement ends on January 1, 2027 and, pursuant to the terms of the Prior Agreement, in the first half of 2026, the parties agreed to discuss in good faith entering into a potential longer-term employment agreement;

WHEREAS, the Company and the Executive desire to enter into this Agreement, which shall supersede the Prior Agreement in its entirety as of the Effective Date, to set forth the rights and obligations of the parties hereto in respect of the Executive's continued employment with the Company and the Executive's service as Chief Executive Officer of Keenova and Chairman of the Board of Directors of Keenova (the "***Board***");

WHEREAS, the Company desires to be assured that the unique and expert services of the Executive will continue to be available to the Company and that the Executive is willing and able to render such services on the terms and conditions hereinafter set forth; and

WHEREAS, the Company desires to be assured that the confidential information and good will of the Company Group will continue to be preserved for the exclusive benefit of the Company Group.

NOW, THEREFORE, in consideration of such employment and the mutual covenants and promises herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive agree as follows:

Section 1. <u>Effective Date; Employment; Position and Location; Appointment as Chair</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company hereby agrees to continue to employ the Executive, effective as of the Effective Date, as the Chief Executive Officer of the Company (and shall be the Company's highest ranking executive) and, in connection therewith but for no remuneration, the Executive will continue to serve as a member of the board of directors and Chief Executive Officer of Keenova (and shall be Keenova's highest ranking officer), and the Executive hereby accepts such continued employment under and subject to the terms and conditions hereinafter set forth. The Executive shall perform his services principally in New Jersey, which is subject to change upon the mutual agreement of the parties**.** Executive acknowledges that he may be required to travel in connection with the performance of his duties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Not later than May 14, 2026, Executive shall be appointed as the Chair of the Board. Subject to such appointment, Executive shall serve as the Chief Executive Officer of the Company and the Chair of the Board. If Executive's appointment as the Chair of the Board is not approved on or prior to May 14, 2026, Executive shall be entitled to resign his employment on or within thirty (30) days following January 1, 2027 and any such resignation shall be treated as a termination by the Executive with Good Reason.

Section 2. <u>Term of Agreement</u>. The term of employment under this Agreement shall be for a period beginning on the Effective Date and ending on January 1, 2028 (the "***Expiration Date***"). Unless the parties mutually agree to extend the term, Executive's employment with the Company and service as the Chief Executive Officer, Chair and/or Executive Chair, as applicable, of Keenova shall automatically terminate on the Expiration Date, which termination shall constitute a termination by the Executive with Good Reason (as defined below). For the avoidance of doubt, at all times, the Company shall have the right to terminate Executive's employment with the Company for any reason.

Section 3. <u>Duties</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Executive shall perform services in a manner consistent with the Executive's position as Chief Executive Officer of the Company and Keenova, subject to the general supervision and direction of the Board. As Chief Executive Officer, all executives of the Company Group shall report directly or indirectly to the Executive. The Executive shall report solely and directly to the Board and, for the avoidance of doubt, shall not report to any specific member of the Board. The Executive hereby agrees to devote substantially all of his business time, skill, attention, and reasonable best efforts to the faithful performance of such duties and to the promotion of the business and affairs of the Company during his employment with the Company. Notwithstanding the foregoing, the Executive may (a) serve on the boards of trade associations and charitable organizations, (b) engage in charitable and educational activities and community affairs, (c) manage the Executive's personal investments and affairs and (d) subject to the Company's approval which shall not be unreasonably withheld, conditioned or delayed, serve on the board of directors of one unaffiliated company. The parties acknowledge that the Executive was appointed as a member of the Board on June 25, 2022, and the Executive acknowledges that he shall perform such services without compensation and such service shall be deemed part of the Executive's duties and responsibilities hereunder. The Company shall use best efforts to cause Executive to be nominated for election to the Board in subsequent years while Executive serves as the Chief Executive Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Executive acknowledges that, during the term, the Board shall endeavor to identify a suitable successor Chief Executive Officer of Keenova. If a search committee is formed, Executive shall participate as a member of such committee. If a successor Chief Executive Officer of Keenova is hired prior to January 1, 2028, Executive acknowledges and agrees that his role will transition to Executive Chair of the Board (the ***"Executive Chair"***) effective upon the commencement of employment of the successor Chief Executive Officer of Keenova. Executive acknowledges and agrees that his transition to Executive Chair pursuant to this Section 3(b) shall not, solely by such transition and the changes to compensation set forth herein, constitute grounds for Executive to terminate his employment for Good Reason.

Section 4. <u>Base Salary</u>. In consideration of the services rendered by the Executive under this Agreement, the Company shall pay the Executive a base salary (the "***Base Salary***") at the rate of one million two hundred thousand dollars ($1,200,000) per calendar year, payable in accordance with the Company's applicable payroll practices. The Base Salary shall be subject to review and increase (but may not decrease, unless the reduction in Base Salary is (i) part of a program approved by the Board, or its delegate, the Human Resources and Compensation Committee (collectively, the "***Committee***") that affects all executives on a consistent basis and (ii) no greater than 10% in the aggregate) by the Committee in its sole discretion. References in this Agreement to "Base Salary" shall be deemed to refer to the most recently effective annual base salary, unless otherwise specifically set forth herein. If Executive transitions to Executive Chair pursuant to Section 3(b) above, effective as of such transition, the Base Salary shall be eighty percent (80%) of Executive's Base Salary immediately prior to such transition.

Section 5. <u>Additional Benefits</u>. In addition to the Base Salary, the Company shall provide the Executive with the following additional benefits:

Section 5.01 <u>Annual Short-Term Management Incentive Plan</u>. The Executive shall be eligible to participate in an annual short-term management incentive plan established by the Committee (the "***STIP***") pursuant to which the Executive will have the opportunity to earn a cash incentive bonus in respect of each year of employment (the "***Annual Bonus***"), subject to terms established by the Committee from time to time. The Executive's annual cash bonus target (the "***Target Bonus***") and maximum cash bonus shall equal 200% of the Base Salary and 400% of the Base Salary, respectively. The actual bonus earned by the Executive in respect of a given year, if any, shall be based on performance metrics to be determined by the Committee, in its sole discretion, after consultation with the Executive. For any calendar year in which Executive transitions to Executive Chair pursuant to Section 3(b) above, (i) the Executive's Annual Bonus shall be determined for the portion of the calendar year occurring prior to the transition on a pro-rata basis using the Base Salary that was in effect for that period, and (ii) the Executive's Annual Bonus shall be determined for the portion of the calendar year following the transition on a pro-rata basis using the Base Salary that was in effect for the period following the transition, provided that the calculation of the Annual Bonus for any period when Executive is serving as Executive Chair shall be prorated using a level of performance that is not less than the Target Bonus for such calendar year. For the avoidance of doubt, except as provided in Section 7.02, the Executive's participation in the STIP and his right to earn any cash bonus thereunder shall be subject to the same terms and conditions established by the Committee for other executive officers of the Company. The Annual Bonus (combining clauses (i) and (ii) above) shall be paid to the Executive in accordance with the STIP and at the same time other executive annual bonuses under the STIP are paid.

Section 5.02 <u>Long-Term Inducement Awards</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to Executive's continued service through January 1, 2027 (except as provided herein), Executive shall be paid a lump sum cash amount of six million dollars ($6,000,000) on or within thirty (30) days following January 1, 2027 (the "***Cash Inducement Award***").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Executive was previously granted an "***Equity Inducement Award****"* in the form of restricted units of Keenova ***("RSUs"***) with a fair value of six million dollars ($6,000,000) calculated as of the effective date of the Prior Agreement, which will cliff vest on January 1, 2027, subject to Executive's continued service through such date, except as provided herein*.* The terms and conditions applicable to the Equity Inducement Award are substantially consistent with the terms and conditions applicable to RSUs previously issued to Executive, except as otherwise set forth herein. For the avoidance of doubt, notwithstanding the terms of the Mallinckrodt 2024 Stock and Incentive Plan or any subsequent plan under which such RSUs may be granted, the terms "Cause," "Disability," and "Good Reason" shall have the meanings set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Beginning in the 2026 fiscal year, Keenova shall provide an annual long-term incentive compensation grant to Executive, which grant shall be for an award of an aggregate of 152,722 RSUs and performance restricted units of Keenova (***"PSUs"***) for fiscal year 2026 and, for fiscal years 2027 and thereafter, shall have a grant date fair market value of no less than eleven million five hundred thousand dollars ($11,500,000) (the "***Annual LTI Awards***"). The terms and conditions applicable to the Annual LTI Awards shall be substantially consistent with the terms and conditions applicable to RSUs and PSUs (other than performance metrics) previously issued to Executive, except as follows or as otherwise set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Keenova shall grant Executive an equity incentive award in the form of RSUs (a "***Founders Grant****"*), at the same time as all other Founders Grants are granted to executives of Keenova, with a value that is no less than 2.3 times the value of the Founders Grant for the executive with the next highest level of participation, that will vest ratably on each of the first through third anniversaries of the grant date, subject to Executive's continued service through each such date, except as provided herein*.* The terms and conditions applicable to the Founders Grant shall be substantially consistent with the terms and conditions applicable to RSUs previously issued to Executive, except as otherwise set forth herein.

Section 5.03 <u>Benefits</u>. The Executive shall be entitled to participate in the Company's health, welfare, and other benefit plans and programs, including vacation, as well as any transaction incentive plans, that are in effect for its executive officers from time to time, subject to the terms and conditions of such plans and such participation in each case shall be on terms and conditions no less favorable to the Executive than executive officers of the Company generally; <u>provided</u>, that such plans may be amended, modified, or terminated at any time so long as Executive is not treated less favorably than executive officers of the Company generally; and <u>provided, further,</u> that the Executive's participation in any transaction incentive plan shall be at no less than 2.3 times the level of participation for the executive with the next highest level of participation. For the avoidance of doubt, the Executive is not entitled to any employment benefits under Irish law and/or the law of any jurisdiction other than the United States, or to the protection of Irish employment legislation and/or employment legislation of any jurisdiction other than the United States as the Executive is not an employee of any member of the Company Group other than the Company.

Section 5.04 <u>Reimbursement of Expenses</u>. The Company shall reimburse the Executive for all reasonable, necessary, and documented expenses actually incurred by the Executive directly in connection with the business affairs of the Company and the performance of his duties hereunder, upon presentation of proper receipts or other proof of expenditure and subject to such reasonable guidelines or limitations that are applicable generally to executive officers of the Company, as provided by the Company from time to time. The Executive shall comply with such reasonable limitations and reporting requirements with respect to such expenses as the Committee may establish from time to time, in each case that are applicable generally to executive officers of the Company. Except to the extent specifically provided, however, the Executive shall not use Company funds for non-business, non-Company related matters or for personal matters.

Section 5.05 <u>Indemnification and D&O Insurance</u>. The Company shall provide Executive with indemnification and liability insurance coverage to the maximum extent permitted by the Company's and its subsidiaries' and affiliates' organizational documents, including directors' and officers' insurance policies, with such indemnification to be on terms determined by the Committee or any of its committees, but on terms no less favorable than provided to any other Company executive officer or director and subject to the terms of any separate written indemnification agreement, and which shall provide for the advancement of related expenses and attorneys' fees.

Section 5.06 <u>Executive Advisory Fees</u>. The Company shall reimburse the Executive for reasonable, documented legal and tax advisory fees incurred by the Executive in connection with the negotiation, drafting and execution of this Agreement (including exhibits).

Section 5.07 <u>Compensation</u>. The Executive agrees and acknowledges that (i) the Executive is employed solely by the Company and not by any member of the Company Group; (ii) the Executive's compensation is paid for the services the Executive renders to the Company; and (iii) in connection with the Executive's employment with the Company, and for no compensation, the Executive serves as a member of the Board and Chief Executive Officer of Keenova.

Section 6. <u>Termination</u>. This Agreement and the Executive's employment hereunder shall be terminated as follows:

Section 6.01 <u>Death</u>. This Agreement and the Executive's employment hereunder shall automatically terminate upon the death of the Executive.

Section 6.02 <u>Disabilit</u>y. In the event of any physical or mental disability of the Executive rendering the Executive substantially unable to perform his duties hereunder for a continuous period of at least 90 days or for at least 120 days out of any twelve (12)-month period after reasonable accommodation that, in any case, meets the requirements for disability benefits under the Company's long-term disability plan (a "***Disability***"), the Executive's employment under this Agreement shall terminate automatically. Any determination of Disability shall be made by the Board in its good faith and reasonable discretion in consultation with a qualified physician or physicians selected by the Executive (or Executive's representatives) and reasonably acceptable to the Board. The failure of the Executive to submit to a reasonable examination by a physician or physicians reasonably acceptable to the Board within thirty (30) day's following the Board's request for such an examination shall act as an estoppel to any objection by the Executive to the determination of Disability by the Board.

Section 6.03 <u>By the Company for Cause</u>. The employment of the Executive may be terminated by the Company for Cause (as defined below) at any time, effective upon written notice to the Executive specifying the event(s) or circumstance(s) constituting Cause. For purposes hereof and of any other agreement between the Executive and any member of the Company Group, the term "***Cause***" shall mean the Executive's: (1) substantial refusal to perform duties and responsibilities of his job as required by the Board, other than due to the Executive's incapacity due to physical or mental illness, which non-performance has continued for thirty (30) days following the Executive's receipt of written notice from the Board of such non-performance; (2) material violation of any fiduciary duty or duty of loyalty owed to the Company Group that has a material adverse effect on the Company Group; (3) conviction of a misdemeanor (other than a traffic offense) involving moral turpitude or felony, in each case, other than Limited Vicarious Liability (as defined below); (4) any willful act or omission constituting fraud, embezzlement or theft; (5) violation of a material rule or policy of the Company Group, which violation is not cured within ten (10) days following the Executive's receipt of written notice from the Board of such violation; or (6) unauthorized disclosure of any trade secret or confidential information of the Company Group. No action or inaction shall be treated as willful unless done or not done in bad faith and without a reasonable belief it was in the best interests of the Company Group. Poor performance shall not in and of itself constitute Cause. Cause shall not occur as a result of actions or inactions based upon directions from the Board. For purposes of this Section 6.03, "***Limited Vicarious Liability***" shall mean any liability, other than liability for omissions by the Executive for which he has a duty under which he has disregarded in gross neglect, which is (A) based on acts of the Company Group for which the Executive is responsible solely as a result of his office(s) with the Company Group and (B) provided that (x) he was not directly involved in such acts and either had no prior knowledge of such intended actions or promptly acted reasonably and in good faith to attempt to prevent the acts causing such liability or (y) he did not have a reasonable basis to believe that a law was being violated by such acts.

Section 6.04 <u>By the Company without Cause</u>. The Company may terminate the Executive's employment at any time without Cause effective upon not less than thirty (30) days' prior written notice to the Executive; <u>provided</u>, that in lieu of providing the notice described above, the Company may, in its sole discretion, continue to pay the Executive his Base Salary during such thirty (30) day period.

Section 6.05 <u>By the Executive Voluntarily</u>. The Executive may terminate this Agreement and his employment hereunder at any time effective upon at least thirty (30) days' prior written notice to the Company; <u>provided</u>, that the Company may, in its sole discretion, within five (5) days of its receipt of such notice, waive such notice period and accelerate the date of the Executive's termination to any date that occurs following the Company's receipt of such notice without changing the characterization of such termination as a resignation, even if such date is prior to the date specified in such notice, and any pay in lieu of such notice period or portion thereof that the Company has so waived is capped at thirty (30) days.

Section 6.06 <u>By the Executive with Good Reason</u>. The Executive may terminate this Agreement effective upon written notice to the Company with Good Reason (as defined below). Such notice must provide a reasonably detailed explanation of the circumstances constituting Good Reason. For purposes of this Agreement, the term "***Good Reason***" shall mean, without the Executive's express written consent: (1) a material reduction in the Executive's Base Salary or Target Bonus opportunity percentage, in either case except as permitted by Section 4; (2) a material diminution in the Executive's title or in the Executive's authority, duties, reporting lines or responsibilities (including failure by the Board to nominate the Executive to the Board and support his election), except as permitted by Section 3(b); (3) a relocation of the Executive's principal place of employment by more than fifty (50) miles; (4) the Executive does not timely receive the Cash Inducement Award, the Equity Inducement Award, any Annual LTI Award or the Founders Grant in accordance with the terms of Section 5.02; (5) failure of a successor to the Company to agree to assume and honor this Agreement; or (6) any other material breach of this Agreement or any material compensation agreement by the Company or its affiliates that is not covered by clause (1), (2), (3), (4) or (5) above. Notwithstanding the foregoing, in the event that the Executive provides written notice of termination with Good Reason in reliance upon this Section 6.06 (such notice to be provided within thirty (30) days of the Executive's knowledge of the occurrence of the events or circumstances constituting Good Reason), the Company shall have the opportunity to cure such circumstances within thirty (30) days of receipt of such notice. If the Company shall not have cured such event or events giving rise to Good Reason within thirty (30) days after receipt of written notice from the Executive, the Executive may terminate employment for Good Reason by delivering a resignation letter to the Company within thirty (30) business days following such thirty (30) day cure period; <u>provided</u>, that if the Executive has not delivered such resignation letter to the Company within such thirty (30) business day period, or has not provided written notice to the Company within thirty (30) days of the occurrence of the events or circumstances constituting Good Reason, the Executive waives the right to terminate employment for Good Reason.

Section 7. <u>Effect of Termination</u>.

Section 7.01 <u>Voluntary Termination without Good Reason, Termination for Cause</u>. Upon any termination of the Executive's employment under this Agreement either (i) voluntarily by the Executive without Good Reason, or (ii) by the Company for Cause, all payments, Base Salary and other benefits hereunder shall cease at the effective date of termination. Notwithstanding the foregoing, the Company shall pay or provide to the Executive (a) all Base Salary earned or accrued through the date the Executive's employment terminates, (b) reimbursement for any and all monies advanced by the Executive in connection with the Executive's employment for reasonable and necessary expenses incurred by the Executive through the date the Executive's employment is terminated, (c) except upon termination of the Executive's employment by the Company for Cause, any unpaid Annual Bonus earned in a prior calendar year, based on the actual level of achievement of the applicable targets or performance as determined by the Committee at the end of such calendar year, and (d) all other payments and benefits to which the Executive may be entitled under the terms of any applicable compensation arrangement or benefit plan or program of the Company, including any earned and accrued, but unused, vacation pay, but excluding any bonus payments (collectively, "***Accrued Benefits***"), except that, for this purpose, Accrued Benefits shall not include any entitlement to severance under any Company Group severance policy generally applicable to the Company's salaried employees.

Section 7.02 <u>Death, Disability, Termination without Cause or Voluntary Termination with Good Reason</u>. In the event that the Executive's employment under this Agreement is terminated by the Company without Cause, by the Executive with Good Reason or as a result of the Executive's death or Disability, the Company shall pay or provide to Executive as his exclusive severance benefit right and remedy in respect of such termination, (i) his Accrued Benefits, except that, for this purpose, Accrued Benefits shall not include entitlement to severance under any Company Group severance policy generally applicable to the Company's salaried employees, (ii) as long as the Executive does not violate in any material respects the provisions of Section 8 and Section 9 hereof, severance pay as follows (collectively, the "***Severance Benefits***"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) an amount equal to the product of (i) the sum of his Base Salary and Target Bonus (in each case, not taking into account, for this and other severance provisions, reductions which would constitute Good Reason or were otherwise made in the prior six (6) months or any reductions as a result of Executive's transition to Executive Chair) multiplied by (ii) 2.5 (the "***Severance Multiplier***"), net of deductions and tax withholdings, as applicable, and payable in a lump sum on the first regular payroll date following the effective date of the Release (as defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) to the extent not yet paid, the Cash Inducement Award, net of deductions and tax withholdings, as applicable, and payable in a lump sum on the first regular payroll date following the effective date of the Release (as defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) to the extent not yet granted or vested, immediate vesting in the Equity Inducement Award;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) a pro-rated portion of the Target Bonus for the calendar year in which the date of Executive's termination occurs, pro-rated for the amount of time the Executive is employed during such calendar year and payable in a lump sum on the first regular payroll date following the effective date of the Release;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) to the extent not yet granted or vested, full and immediate vesting in the Founders Grant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) any Annual LTI Awards granted in 2026 or later shall be treated in accordance with the applicable plan and related award agreements, provided that, notwithstanding anything in the applicable plan or award agreements to the contrary, to the extent Executive's termination without Cause or for Good Reason occurs following the parties failing to mutually agree to extend the term beyond the Expiration Date, Executive shall immediately vest in any RSUs that would have otherwise vested in the first quarter of 2028 and shall immediately vest in a prorated portion of any outstanding but unvested PSUs as of the date of termination of the target number of PSUs subject to such awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) except as otherwise explicitly set forth herein, all outstanding equity-based awards held by the Executive that were granted under the Mallinckrodt 2024 Stock and Incentive Plan or the Keenova 2025 Stock and Incentive Plan, including, without limitation, the Initial Grant, as such term is defined in Executive's Second Amended and Restated Employment Agreement entered into on February 2, 2024, shall be treated in accordance with the terms of the applicable plan and related award agreements; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) if continued coverage under the Company's health and welfare plans is timely elected by the Executive, payment of any insurance premiums pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, and the regulations promulgated thereunder ("***COBRA***") from the date of the Executive's termination until the earlier of (i) the thirtieth (30) month anniversary of the date of the Executive's termination, (ii) the first date that the Executive is no longer eligible for Company-provided COBRA coverage, and (iii) the date the Executive has commenced new employment and has thereby become eligible for comparable benefits; provided, however, that if Executive is no longer eligible for Company-provided COBRA coverage prior to the thirtieth (30) month anniversary of the date of Executive's termination and Executive has not commenced new employment and become eligible for comparable benefits from a new employer, the Executive shall receive monthly cash payments of the amount of the applicable COBRA premium until the earlier of the thirtieth (30) month anniversary of the date of Executive's termination and the date the Executive has commenced new employment and has thereby become eligible for comparable benefits**.**

Section 7.03 <u>Accrued Benefits</u>. Notwithstanding anything else herein to the contrary, all Accrued Benefits to which the Executive (or his estate or beneficiary) is entitled shall be payable in cash promptly upon the effective date of termination, except as otherwise specifically provided herein, or under the terms of any applicable policy, plan, or program; <u>provided</u>, that all Accrued Benefits shall be paid no later than December 31 of the calendar year immediately following the calendar year of the Executive's termination.

Section 7.04 <u>No Other Benefits</u>. Except as explicitly provided in this Section 7, the Executive shall not be entitled to any compensation, severance, or other benefits from the Company Group upon or following the termination of the Executive's employment for any reason whatsoever. Notwithstanding anything else herein to the contrary, all payments and benefits due to the Executive under this Section 7 after termination of employment which are not otherwise required by law (other than Accrued Benefits) shall be contingent upon execution by the Executive (or the Executive's beneficiary or estate) of a general release of all claims, to the maximum extent permitted by law, against the Company Group, its affiliates, and its then current and former equity holders, directors, employees, and agents, in substantially the form attached hereto as <u>Exhibit A</u> (the "***Release***") and such Release becoming irrevocable no later than thirty (30) days following the Executive's termination of employment.

Section 7.05 <u>Resignation as an Officer and Director</u>. If the Executive's employment with the Company terminates for any reason (including termination of employment as Executive Chair), the Executive will be deemed to have automatically resigned, effective as of the date of termination of his employment with the Company, from all positions with the Company Group (including as a member of the Board), unless otherwise mutually agreed by the parties in writing, and the Executive agrees to execute any documents needed to effect the foregoing.

Section 7.06 <u>No Mitigation</u>. The Executive shall not be required to mitigate the amount of any payment provided pursuant to Section 7 by seeking other employment or otherwise, and the amount of any payment provided for pursuant to Section 7 shall not be reduced by any compensation earned as a result of the Executive's other employment or otherwise.

Section 7.07 <u>Survival of Certain Provisions</u>. Provisions of this Agreement shall survive any termination of the Executive's employment if so provided herein, including, without limitation, the obligations of the Executive under Sections 8 and 9 hereof. The obligation of the Company to make payments to or on behalf of the Executive under this Section 7 hereof is expressly conditioned upon the Executive's continued performance in all material respects of Executive's obligations under Section 8 and Section 9 hereof; provided, that the Company shall provide the Executive with written notice of any such failure to perform and not less than thirty (30) days to cure, if curable. The Executive recognizes that, except as expressly provided in this Section 7, no compensation shall be earned after termination of employment.

Section 8. <u>Confidentiality; Assignment of Inventions</u>.

Section 8.01 <u>Confidentiality</u>. The Executive acknowledges that he is in possession of confidential information concerning the business and operations of the Company Group, including the identity of customers and suppliers (the "***Confidential Information***"). The Executive agrees that he shall keep all such Confidential Information strictly confidential and use such Confidential Information only for the purpose of fulfilling his obligations hereunder and in order to perform any service to the Company Group as a director, consultant, or employee, and not for any other purpose. Notwithstanding the foregoing, Confidential Information shall not include any information that (i) has become publicly known and made generally available or is known within the Company Group's industry through no wrongful act of the Executive or (ii) is required to be disclosed by applicable laws, court order or subpoena or a governmental or regulatory agency (or similar body or entity) after, to the extent legally permitted, providing prompt written notice of such request to the Board so that the Company Group may seek an appropriate protective order or other appropriate remedy. The Executive may also disclose Confidential Information to the extent required pursuant to any legal process between the Executive and the Company Group.

Section 8.02 <u>Assignment of Inventions</u>. The Executive agrees to assign and transfer to the Company or its designee, without any separate remuneration or compensation, his entire right, title, and interest in and to all Inventions (as defined below), together with all United States and foreign rights with respect thereto, and at the Company Group's expense to execute and deliver all appropriate patent and copyright applications for securing United States and foreign patents and copyrights on Inventions, and to perform all lawful acts, including giving testimony, and to execute and deliver all such instruments that may be necessary or proper to vest all such Inventions and patents and copyrights with respect thereto in the Company Group, and to assist the Company Group in the prosecution or defense of any interference which may be declared involving any of said patent applications, patents, copyright applications, or copyrights. For the purposes of this Agreement, "***Inventions***" shall mean any discovery, process, design, development, improvement, application, technique, or invention, whether patentable or copyrightable or not and whether reduced to practice or not, conceived or made by the Executive, individually or jointly with others (whether on or off the Company's premises or during or after normal working hours), while in the employ of the Company and (x) which was or is directly or indirectly related to the business of the Company Group or (y) which resulted or results from any work performed by any executive or agent thereof during the Executive's employment with the Company.

Section 8.03 <u>Return of Documents upon Termination of Employment</u>. All notes, letters, documents, records, tapes, and other media of every kind and description relating to the business, present or otherwise, of the Company Group, and any copies, in whole or in part, thereof (collectively, the "***Documents***"), whether or not prepared by the Executive, shall be the sole and exclusive property of the Company Group. The Executive shall safeguard all Documents and shall surrender to the Company at the time his employment terminates, or at such earlier time or times as the Board or its designee may specify, all Documents then in the Executive's possession or control. Notwithstanding the foregoing, the Executive may retain all information, documentation and devices personal to the Executive; <u>provided</u> that such materials do not contain Confidential Information, and the Company will cooperate in transferring any personal information from Company devices to the Executive's personal devices.

Section 8.04 <u>Whistleblower Acknowledgement</u>. Notwithstanding anything to the contrary contained herein, nothing in this Agreement shall prohibit the Executive from reporting possible violations of federal law or regulation to or otherwise cooperating with or providing information requested by any governmental agency or entity, including, but not limited to, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. The Executive does not need the prior authorization of the Company to make any such reports or disclosures and the Executive is not required to notify the Company that he has made such reports or disclosures.

Section 8.05 <u>Trade Secret Acknowledgement</u>. Notwithstanding anything to the contrary contained herein, the Executive will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that is made: (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose the Company Group's trade secrets to his attorney and use the trade secret information in the court proceeding if the Executive: (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.

Section 9. <u>Restrictions on Activities of the Executive</u>.

Section 9.01 <u>Acknowledgments</u>. The Executive and the Company agree that the Executive is being employed hereunder in a key capacity with the Company and that the Company Group is engaged in a highly competitive business and that the success of the Company Group's business in the marketplace depends upon its good will and reputation for quality and dependability. The Executive and the Company further agree that reasonable limits may be placed on the Executive's ability to compete against the Company Group as provided herein to the extent that they protect and preserve the legitimate business interests and good will of the Company Group and are reasonable and valid in geographical and temporal scope and in all other respects. Notwithstanding anything to the contrary herein, the covenants contained in this Section 9 shall be in addition to, and not in lieu of, and shall not amend, modify, abrogate, or otherwise alter any other restrictive covenants by which the Executive is bound pursuant to any other written agreement with the Company Group**.**

Section 9.02 <u>Restrictions</u>. During the Executive's employment with the Company and during the twelve (12) month period following the date of the Executive's termination from employment with the Company for any reason (the "***Restricted Period***"; provided that with respect to clause (a), the Restricted Period shall not apply following the Executive's termination of employment if the date of termination is on or after the Expiration Date or if Executive's employment is terminated by the Company without Cause or by Executive with Good Reason), the Executive shall not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) directly or indirectly engage in, provide services to, have any equity interest in, or manage or operate any individual, firm, corporation, partnership, business or entity (a "***Business***") (whether as director, officer, employee, principal, agent, representative, owner, partner, member, security holder, consultant or otherwise) that engages in (either directly or through any subsidiary or parent thereof) any business or activity in any geographic location in which the Company Group engages in, whether through selling, distributing, manufacturing, marketing, purchasing, or otherwise, that competes with any of the businesses of the Company Group or any entity owned by the Company Group (a "***Competing Business***"); provided that a "Competing Business" shall not include (i) hospitals or pharmacies that purchase Company Group products or similar products or (ii) retailers or wholesalers that sell Company Group products or similar products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) directly or indirectly solicit or recruit, on his own behalf or on behalf of any other Business, the services of, or hire or engage, or interfere with the Company Group's relationship with, any individual who is (or, at any time during the previous twelve (12) months, was) an employee, independent contractor or director of the Company Group, or solicit any of the Company Group's then-current employees, independent contractors or directors to terminate services with the Company Group; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) directly or indirectly, on his own behalf or on behalf of any other Business, recruit or otherwise solicit for a Competing Business, any customer, client, distributor, vendor, supplier, licensee, licensor or other business relation of the Company Group, or encourage or induce any such Person to terminate its arrangement with the Company Group or otherwise change or interfere with its relationship with the Company Group.

Notwithstanding the foregoing, none of the following activities shall constitute a violation of this Section 9.02 to the extent (and solely to the extent) set forth in this paragraph: (i) the solicitation (but not hiring) by advertisement of job openings by use of newspapers, magazines, the Internet, other media, and search firms not directed at individual prospective employees covered by this Section 9.02 shall not violate Section 9.02(b); (ii) providing a reference for an employee or independent contractor shall not violate Section 9.02(b); (iii) soliciting or hiring an independent contractor or director who is not exclusive to the Company shall not violate Section 9.02(b) so long as Executive does not solicit such an independent contractor to terminate services with the Company Group; (iv) holding not more than five percent (5%) of the outstanding securities of any class of any securities of a company or other entity that is engaged in a Competing Business shall not violate Section 9.02(a); and (v) providing services to a unit, division, subsidiary or affiliate of an entity engaging in a Competing Business if the unit, division, subsidiary or affiliate for which the Executive is providing services is not engaging in the Competing Business. The Restricted Period for the applicable provision shall be tolled during (and shall be deemed automatically extended by) any period in which the Executive is in violation of any of the provisions of this Section 9.02.

Section 9.03 THE EXECUTIVE REPRESENTS AND WARRANTS THAT THE KNOWLEDGE, SKILLS, AND ABILITIES HE POSSESSES AT THE TIME OF COMMENCEMENT OF EMPLOYMENT HEREUNDER ARE SUFFICIENT TO PERMIT HIM, IN THE EVENT OF TERMINATION OF HIS EMPLOYMENT HEREUNDER, TO EARN A LIVELIHOOD SATISFACTORY TO HIMSELF WITHOUT VIOLATING ANY PROVISION OF SECTION 8 OR 9 HEREOF, FOR EXAMPLE, BY USING SUCH KNOWLEDGE, SKILLS, AND ABILITIES, OR SOME OF THEM, IN THE SERVICE OF A NON-COMPETITOR.

Section 9.04 <u>Non-Disparagement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Executive shall not, during the term of his employment or at any time thereafter, whether in writing or orally, malign, denigrate, or disparage the Company Group, or any current or former directors, officers, or employees of the Company Group, with respect to any of their respective past or present activities, or otherwise publish (whether in writing or orally) statements that tend to portray any of the aforementioned parties in an unfavorable light. The Executive understands that nothing in this Agreement is intended to prevent Executive from making truthful statements (i) in any legal proceeding or as otherwise required by law, or from reporting possible violations of federal law or regulation to a governmental agency or entity; (ii) when requested by a governmental, regulatory, or similar body or entity; (iii) in confidence to a professional advisor for the purpose of securing professional advice; (iv) in the course of performing Executive's duties during the Executive's term of employment (e.g., performance reviews); or (v) in response to statements, references or characterizations made, directly or indirectly, by the Company Group that are misleading, disparage the Executive, or reflect negatively on the Executive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company Group shall instruct the members of the Board and its executive officers not to make any statements, during the term of the Executive's employment or at any time thereafter, that disparage the Executive and neither the Company Group nor the Board shall make any public official statement disparaging Executive, except in response to statements, references or characterizations made, directly or indirectly, by the Executive that are misleading, disparage the Company Group, or reflect negatively on the Company Group, regarding the circumstances of the Executive's employment.

Section 10. <u>Remedies</u>. It is expressly understood and agreed that, notwithstanding anything to the contrary herein, in the event of any breach of the provisions of Section 8 or 9 of this Agreement, the Company Group shall have the right and remedy, without regard to any other available remedy, to (i) have the restrictive covenants set forth in Section 8 or 9 specifically enforced by any court of competent jurisdiction, (ii) seek to have issued an injunction restraining any breach or threatened breach without posting of a bond, and (iii) seek any and all other remedies available to the Company Group under applicable law; it being understood that any breach of any of the restrictive covenants set forth in Section 8 or 9 could cause irreparable and material damages to the Company Group (including, for the avoidance of doubt, any loss of the proprietary advantage and trade secrets related to the identity of customers and suppliers), the amount of which cannot be readily determined and as to which the Company Group will not have any adequate remedy at law or in damages. The Executive agrees that any remedy at law for any breach by the Executive of the restrictive covenants set forth in Section 8 or 9 would be inadequate, and that the Company Group would be entitled to seek injunctive relief in such a case. If it is ever held that these restrictions on the Executive are too onerous and are not necessary for the protection of the Company Group, the Executive agrees that any court of competent jurisdiction may impose such lesser restrictions that may be necessary or appropriate to properly protect the Company Group. For the avoidance of doubt, the failure in one or more instances of the Company Group to insist upon performance of any of the covenants or restrictive covenants set forth in Section 8 or 9, to exercise any right or privilege herein conferred, or the waiver by the Company Group of any breach of any of the covenants or restrictive covenants set forth in Section 8 or 9 shall not be construed as a subsequent waiver by the Company Group of any breach of any of the covenants or restrictive covenants set forth in Section 8 or 9, but the same shall continue and remain in full force and effect as if no forbearance or waiver had occurred.

Section 11. <u>Severable Provisions</u>. The provisions of this Agreement are severable and the invalidity of any one or more provisions shall not affect the validity of any other provision. In the event that a court of competent jurisdiction shall determine that any provision of this Agreement or the application thereof is unenforceable in whole or in part because of the duration or scope thereof, the parties hereto agree that said court in making such determination shall have the power to reduce the duration and scope of such provision to the extent necessary to make it enforceable, and that the Agreement in its reduced form shall be valid and enforceable to the full extent permitted by law.

Section 12. <u>Notices</u>. Any and all notices or other communication required or permitted to be given under any of the provisions of this Agreement shall be in writing and shall be deemed to have been duly given (i) upon delivery if personally delivered, (ii) three (3) days after deposit if sent by first class registered mail, return receipt requested, (iii) one (1) day after deposit if sent by a reputable overnight courier, or (iv) upon confirmation if sent by facsimile or email, addressed to the parties at the addresses set forth below (or at such other address as any party may specify by notice to all other parties given as aforesaid):

---

| | |
|:---|:---|
| If to the Company: | ST Shared Services LLC |
|  | 440 Route 22 East, Suite 302 |
|  | Bridgewater, NJ 08807 |
|  | Attention: Chief Legal Officer and Corporate Secretary |
|  | Email: corporate.secretary@mnk.com |
|  | with a copy to: |
|  | Hogan Lovells US LLP |
|  | 100 International Drive, Suite 2000 |
|  | Baltimore, Maryland 21202 |
|  | Attention: William Intner |
|  | Email: William.intner@hoganlovells.com |

---

---

| | |
|:---|:---|
| If to the Executive: | at the most recent address on file for the Executive in the Company's records |
|  | with a copy to: |
|  | Michael S. Katzke |
|  | Katzke Miller & Morgenbesser LLP |
|  | 1095 Park Avenue, Apt. 18A |
|  | New York, New York 10128 |
|  | Email: katzke@kmexeccomp.com |

---

or to such other address as a party may notify the other pursuant to a notice given in accordance with this Section 12.

Section 13. <u>Miscellaneous</u>.

Section 13.01 <u>Amendment</u>. This Agreement may not be amended or revised except by a writing signed by the parties.

Section 13.02 <u>Assignment and Transfer</u>. The provisions of this Agreement shall be binding on and shall inure to the benefit of any successor in interest to the Company. Neither this Agreement nor any of the rights, duties, or obligations of the Executive or the Company shall be assignable by the Executive or the Company, except with respect to a successor, nor shall any of the payments required or permitted to be made to the Executive by this Agreement be encumbered, transferred, or in any way anticipated, except as required by applicable laws. This Agreement shall not be terminated by, nor shall it be deemed an assignment of this Agreement upon, the merger or consolidation of the Company with any corporate or other entity or by the transfer of all or substantially all of the assets of the Company to any other person, corporation, firm, or entity. However, all rights of the Executive under this Agreement shall inure to the benefit of and be enforceable by the Executive's personal or legal representatives, estates, executors, administrators, heirs, and beneficiaries. All amounts payable to the Executive hereunder shall be paid, in the event of the Executive's death, to the Executive's estate, heirs, or representatives.

Section 13.03 <u>Waiver of Breach</u>. A waiver by the Company or the Executive of any breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any other or subsequent breach by the other party.

Section 13.04 <u>Entire Agreement</u>. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements (including, without limitation, the Prior Agreement), understandings, negotiations, and discussions, whether oral or written, of the parties, including, without limitation, any term sheet related to the subject matter hereof. For the avoidance of doubt, the Company and the Executive acknowledge and agree that the Executive shall not be entitled to any payments under the Prior Agreement following the Effective Date.

Section 13.05 <u>Withholding</u>. The Company shall withhold from any amounts to be paid or benefits provided to the Executive hereunder any federal, state, local, or foreign withholding or other taxes or charges which it is from time to time required to withhold. The Company shall be entitled to rely on an opinion of counsel if any question as to the amount or requirement of any such withholding shall arise.

Section 13.06 <u>Captions</u>. Captions herein have been inserted solely for convenience of reference and in no way define, limit, or describe the scope or substance of any provision of this Agreement.

Section 13.07 <u>Counterparts</u>. This Agreement may be executed in one or more counterparts (including by facsimile transmission or electronic image scan (PDF)), each of which shall be deemed an original and shall have the same effect as if the signatures hereto and thereto were on the same instrument.

Section 13.08 <u>Governing Law; No Construction Against Drafter</u>. This Agreement shall be construed under and enforced in accordance with the laws of the State of New York without regard to conflicts of law principles. No provision of this Agreement or any related document will be construed against or interpreted to the disadvantage of any party hereto by any court or other governmental or judicial authority by reason of such party having or being deemed to have structured or drafted such provision.

Section 13.09 <u>Dispute Resolution</u>. Any controversy or claim between the Executive and the Company arising out of or relating to or concerning this Agreement or any aspect of the Executive's employment with the Company or the termination of that employment will be finally settled by binding arbitration in New York, New York administered by the American Arbitration Association under its Rules for the Resolution of Employment Disputes; <u>provided</u>, <u>however</u>, that with respect to any controversy or claim arising out of or relating to or concerning injunctive relief for the Executive's breach or purported breach of Section 8 or 9 of this Agreement, the Company will have the right, in addition to any other remedies it may have, to seek specific performance and injunctive relief with a court of competent jurisdiction, without the need to post a bond or other security. Each of the Executive and the Company will bear its own legal expenses and will share the arbitration costs equally.

Section 13.10 <u>Representations of Executive; Advice of Counsel</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Executive represents, warrants, and covenants that as of the Effective Date: (i) the Executive has the full right, authority, and capacity to enter into this Agreement and perform the Executive's obligations hereunder, (ii) the Executive is not, and will not be, bound by any agreement that conflicts with or prevents or restricts the full performance of the Executive's duties and obligations to the Company hereunder during or after his employment with the Company, and (iii) the execution and delivery of this Agreement shall not result in any breach or violation of, or a default under, any existing obligation, commitment, or agreement to which the Executive is subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prior to execution of this Agreement, the Executive was advised by the Company of the Executive's right to seek independent advice from an attorney of the Executive's own selection regarding this Agreement. The Executive acknowledges that the Executive has entered into this Agreement knowingly and voluntarily and with full knowledge and understanding of the provisions of this Agreement after being given the opportunity to consult with counsel. The Executive further represents that in entering into this Agreement, the Executive is not relying on any statements or representations made by any of the Company's directors, officers, employees, or agents which are not expressly set forth herein, and that the Executive is relying only upon the Executive's own judgment and any advice provided by the Executive's attorney.

Section 13.11 <u>Code Section 409A</u>. Notwithstanding anything to the contrary contained in this Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Internal Revenue Code of 1986, as amended (the "***Code***"), and the regulations and guidance promulgated thereunder to the extent applicable (collectively, "***Code Section 409A***"), and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Code Section 409A. If any provision of this Agreement contravenes Code Section 409A or would cause the Executive to be subject to additional taxes, interest or penalties under Code Section 409A the Executive and the Company shall discuss in good faith modifications to this Agreement in order to mitigate or eliminate such taxes, interest or penalties. In making such modifications the Company and the Executive shall reasonably attempt to maintain the original intent of the applicable provision without contravening the provisions of Code Section 409A to the maximum extent practicable. In no event whatsoever will the Company be liable for any additional tax, interest, or penalties that may be imposed on the Executive under Code Section 409A or any damages for failing to comply with Code Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits considered "***nonqualified deferred compensation***" under Code Section 409A upon or following a termination of employment unless such termination is also a "***separation from service***" within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a "termination," "termination of employment" or like terms shall mean "separation from service." If the Executive is deemed on the date of termination to be a "***specified employee***" within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered nonqualified deferred compensation under Code Section 409A payable on account of a "separation from service," such payment or benefit shall be made or provided at the date which is the earlier of (i) the expiration of the six (6)-month period measured from the date of such "separation from service" of the Executive, and (ii) the date of the Executive's death (the "***Delay Period***"). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section 13.11(b) (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed on the first business day following the expiration of the Delay Period to the Executive in a lump sum with interest during the Delay Period at the prime rate, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits, to be provided in any other taxable year, <u>provided</u>, <u>that</u>, this clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect, and (iii) such payments shall be made on or before the last day of the Executive's taxable year following the taxable year in which the expense occurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) For purposes of Code Section 409A, the Executive's right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g., "payment shall be made within thirty (30) days following the date of termination"), the actual date of payment within the specified period shall be within the sole discretion of the Company

Section 13.12 <u>Code Section 280G</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If there is a change of ownership or effective control or change in the ownership of a substantial portion of the assets of the Company (within the meaning of Section 280G of the Code) (a "***280G Change in Control***") and any payment or benefit (including payments and benefits pursuant to this Agreement) that the Executive would receive from the Company or otherwise (a "***Transaction Payment***") would (i) constitute a "***parachute payment***" within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the "***Excise Tax***"), then the Company shall cause to be determined, before any amounts of the Transaction Payment are paid to the Executive, which of the following two alternative forms of payment would result in the Executive's receipt, on an after-tax basis, of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to the Excise Tax: (A) payment in full of the entire amount of the Transaction Payment (a "***Full Payment***"), or (B) payment of only a part of the Transaction Payment so that the Executive receives the largest payment possible without the imposition of the Excise Tax (a "***Reduced Payment***", and Executive shall be entitled to payment of whichever amount that shall result in a greater after-tax amount for Executive. For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate reasonably applicable to Executive, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is made, the reduction in payments and/or benefits will occur in the following order: (1) first, reduction of cash payments, in reverse order of scheduled payment date (or if necessary, to zero), (2) then, reduction of non-cash and non-equity benefits provided to the Executive, on a pro rata basis (or if necessary, to zero) and (3) then, cancellation of the acceleration of vesting of equity award compensation in the reverse order of the date of grant of the Executive's equity awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Unless the Executive and the Company otherwise agree in writing, any determination required under this section shall be made in writing by a nationally recognized accounting firm selected by the Company subject to the approval of the Executive which shall not be unreasonably withheld (the "***Accountants***"), whose determination shall be conclusive and binding upon the Executive and the Company for all purposes absent manifest error. For purposes of making the calculations required by this section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. Without limiting the generality of the foregoing, any determination by the Accountants under this Section 13.12(b) will take into account the value of any reasonable compensation for services to be rendered by the Executive (or for holding oneself out as available to perform services and refraining from performing services (such as under a covenant not to compete)). The Accountants shall provide detailed supporting calculations to the Company and the Executive as requested by the Company or the Executive. The Executive and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this section. The Company shall bear all costs the Accountants may incur in connection with any calculations contemplated by this section as well as any costs incurred by the Executive with the Accountants for tax planning under Sections 280G and 4999 of the Code. The Company agrees to use all reasonable efforts to submit any Transaction Payments to the Company's stockholders for approval in accordance with Treasury Reg. Section 1.280G-1 Q&A 7, if such stockholder approval is applicable and if requested in writing by Executive.

Section 13.13 <u>Recoupment</u>. By executing this Agreement, the Executive acknowledges and agrees that the compensation provided under this Agreement is subject to recoupment in accordance with the terms and provisions of Keenova's Executive Financial Recoupment Program as in effect on the Effective Date (the "***Recoupment Policy***"), attached hereto as <u>Exhibit B</u>, as such Recoupment Policy may be amended by the Board in compliance with the conditions set forth in Section 6.8 of the Recoupment Policy; provided, that, no application of the Recoupment Policy nor any such amendment shall treat the Executive less favorably than other executive officers of the Company are treated generally.

[*remainder of page intentionally left blank*]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

---

| | |
|:---|:---|
| **ST SHARED SERVICES LLC** | **ST SHARED SERVICES LLC** |
| By: | /s/ Mark Tyndall |
| Name: | Mark Tyndall |
| Title: | Vice President |
| **EXECUTIVE** | **EXECUTIVE** |
| /s/ Sigurdur Olafsson | /s/ Sigurdur Olafsson |
| Sigurdur Olafsson | Sigurdur Olafsson |

---

[*Signature Page to Sigurdur Olafsson Employment Agreement*]

**<u>Exhibit A</u>**

**RELEASE OF CLAIMS ("<u>Release</u>")**

In connection with the termination of employment of Sigurdur Olafsson (the "<u>Executive</u>") by ST Shared Services LLC, a Delaware limited liability company (the "<u>Company</u>"), pursuant to the Fourth Amended and Restated Employment Agreement between Executive and the Company, dated as of _____ ___, 2026 (the "<u>Employment Agreement</u>"), Executive agrees as follows:

1. <u>Release of Claims</u> 

In consideration of the payments and benefits described in Section 7.02 of the Employment Agreement (other than Accrued Benefits), to which Executive agrees that Executive is not entitled until and unless Executive executes this Release and it becomes effective in accordance with the terms hereof, Executive, for and on behalf of himself and his heirs, successors, and assigns, subject to the last sentence of this Section 1, hereby waives and releases any employment, compensation, or benefit-related common law, statutory, or other complaints, claims, charges, or causes of action, both known and unknown, in law or in equity (collectively, the "<u>Claims</u>"), which Executive ever had, now has, or may have against the Company, Keenova Therapeutics plc, a public company with limited liability incorporated in Ireland, and their respective subsidiaries and affiliates, and their equity holders, parents, subsidiaries, successors, assigns, directors, officers, partners, members, managers, employees, trustees (in their official and individual capacities), employee benefit plans and their administrators and fiduciaries (in their official and individual capacities), representatives, or agents, and each of their affiliates, successors, and assigns, (collectively, the "<u>Releasees</u>") by reason of facts or omissions which have occurred on or prior to the date that Executive signs this Release, including, without limitation, any complaint, charge, or cause of action arising out of Executive's employment or termination of employment (including failure to provide notice of termination), or any term or condition of that employment, or claim for severance, equity, or equity-based compensation, except as set forth in Section 7.02 of the Employment Agreement, or arising under federal, state, or local laws pertaining to employment, including the Age Discrimination in Employment Act of 1967 ("<u>ADEA</u>," a law which prohibits discrimination on the basis of age), the Older Workers Benefit Protection Act, the National Labor Relations Act, the Civil Rights Act of 1991, the Americans With Disabilities Act of 1990, Title VII of the Civil Rights Act of 1964, the Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act, the Sarbanes-Oxley Act of 2002, all as amended, and any other federal, state, and local laws relating to discrimination on the basis of age, sex, or other protected class, all Claims under federal, state, or local laws for express or implied breach of contract, wrongful discharge, defamation, intentional infliction of emotional distress, and any Claims for attorneys' fees and costs with respect to any of the foregoing.

Executive further agrees that this Release may be pleaded as a full defense to any action, suit, arbitration, or other proceeding covered by the terms hereof which is or may be initiated, prosecuted, or maintained by Executive, Executive's descendants, dependents, heirs, executors, administrators, or permitted assigns. By signing this Release, Executive acknowledges that Executive intends to waive and release any Claims known or unknown that Executive may have against the Releasees under these and any other laws; <u>provided</u>, that Executive does not waive or release Claims with respect to (i) any rights he may have to enforce the Employment Agreement, (ii) accrued vested benefits or any other benefits remaining due under employee benefit plans of the Company and its subsidiaries and affiliates subject to the terms and conditions of such plans and applicable law, (iii) any rights to continuation of medical and/or dental coverage in accordance with COBRA, (iv) any claims to coverage under any indemnification agreement or policy or liability insurance arrangement, (v) any rights in vested equity or equity-based or transaction-based awards (or in any such awards which will be vested) and (vi) any other rights that may not be released in accordance with applicable law (collectively, the "<u>Unreleased Claims</u>").

2. <u>Proceedings</u> 

Executive acknowledges that Executive has not filed any complaint, charge, claim, or proceeding with respect to a Claim, except with respect to an Unreleased Claim, if any, against any of the Releasees before any local, state, or federal agency, court, or other body (each individually a "<u>Proceeding</u>"). Executive represents that Executive is not aware of any basis on which such a Proceeding could reasonably be instituted. Executive (i) acknowledges that Executive will not initiate or cause to be initiated on his behalf any Proceeding and will not participate in any Proceeding, in each case, except as required by law and (ii) waives any right Executive may have to benefit in any manner from any relief (whether monetary or otherwise) arising out of any Proceeding, including any Proceeding conducted by the Equal Employment Opportunity Commission ("<u>EEOC</u>"). Further, Executive understands that, by executing this Release, Executive will be limiting the availability of certain remedies that Executive may have against the Company and limiting also the ability of Executive to pursue certain claims against the Releasees. Notwithstanding the above, nothing in Section 1 of this Release shall prevent Executive from (i) initiating or causing to be initiated on his behalf any complaint, charge, claim, or proceeding against the Company before any local, state, or federal agency, court, or other body challenging the validity of the waiver of his or her claims under the ADEA contained in Section 1 of this Release (but no other portion of such waiver); or (ii) initiating or participating in an investigation or proceeding conducted by the EEOC.

3. <u>Time to Consider</u> 

Executive acknowledges that Executive has been advised that he has twenty-one (21) days from the date of receipt of this Release to consider all the provisions of this Release and to the extent Executive signs this Release prior to the expiration of such period he does hereby knowingly and voluntarily waive the remaining portion of such twenty-one (21) day period. EXECUTIVE FURTHER ACKNOWLEDGES THAT EXECUTIVE HAS READ THIS RELEASE CAREFULLY, HAS BEEN ADVISED BY THE COMPANY TO, AND HAS IN FACT, CONSULTED AN ATTORNEY, AND FULLY UNDERSTANDS THAT BY SIGNING BELOW EXECUTIVE IS GIVING UP CERTAIN RIGHTS WHICH HE MAY HAVE TO SUE OR ASSERT A CLAIM AGAINST ANY OF THE RELEASEES, AS DESCRIBED IN SECTION 1 OF THIS RELEASE AND THE OTHER PROVISIONS HEREOF. EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS NOT BEEN FORCED OR PRESSURED IN ANY MANNER WHATSOEVER TO SIGN THIS RELEASE, AND EXECUTIVE AGREES TO ALL OF ITS TERMS VOLUNTARILY.

4. <u>Revocation</u> 

Executive hereby acknowledges and understands that Executive shall have seven (7) days from the date of execution of this Release to revoke this Release (including, without limitation, any and all Claims arising under the ADEA) and that neither the Company nor any other person is obligated to provide any benefits to Executive pursuant to the Employment Agreement until eight (8) days have passed since Executive's signing of this Release without Executive having revoked this Release, in which event the Company immediately shall arrange and/or pay for any such benefits otherwise attributable to said eight (8) day period, consistent with the terms of the Employment Agreement. If Executive revokes this Release, Executive will be deemed not to have accepted the terms of this Release, and no action will be required of the Company under any section of this Release.

5. <u>No Admission</u> 

This Release does not constitute an admission of liability or wrongdoing of any kind by Executive or the Company or any of the Releasees.

6. <u>Indemnification</u> 

The Executive shall be entitled to indemnification to the maximum extent permitted by law with regard to actions or inactions taken in good faith performance of the Executive's duties to the Company, and to the extent applicable, the Releasees, during the Executive's employment and to directors and officers liability insurance coverage in accordance with the Company's policies that cover officers and directors generally. Such indemnification and coverage shall apply, while potential liability exists, to the same extent as provided to active directors and senior officers.

7. <u>General Provisions</u> 

A failure of any of the Releasees to insist on strict compliance with any provision of this Release shall not be deemed a waiver of such provision or any other provision hereof. If any provision of this Release is determined to be so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable, and in the event that any provision is determined to be entirely unenforceable, such provision shall be deemed severable, such that all other provisions of this Release shall remain valid and binding upon Executive and the Releasees.

8. <u>Governing Law; Dispute Resolution</u> 

This Release shall be construed under and enforced in accordance with the laws of the State of New York without regard to conflicts of law principles. Any controversy or claim between the Executive and the Company or any Releasee arising out of or relating to or concerning this Release or any aspect of the Executive's employment with the Company or the termination of that employment will be finally settled by binding arbitration in New York, New York administered by the American Arbitration Association under its Rules for the Resolution of Employment Disputes; <u>provided</u>, <u>however</u>, that with respect to any controversy or claim arising out of or relating to or concerning injunctive relief for the Executive's breach or purported breach of Section 8 or 9 of the Employment Agreement, the Company will have the right, in addition to any other remedies it may have, to seek specific performance and injunctive relief with a court of competent jurisdiction, without the need to post a bond or other security. Each of the Executive and the Company will bear its own legal expenses and will share the arbitration costs equally.

IN WITNESS WHEREOF, Executive has hereunto set his hand as of the day and year set forth opposite his signature below.

---

| | |
|:---|:---|
|  | **EXECUTIVE** |
| DATE | Sigurdur Olafsson |
| **(Not to be signed prior to termination of services)** |  |

---

[*Signature Page to Siggi Olafsson Release*]

**<u>Exhibit B</u>**

**EXECUTIVE FINANCIAL RECOUPMENT PROGRAM ("<u>Recoupment Policy</u>")**